MPO and rheumatoid arthritis: To translate this synergistic strategy into clinical practice, key research priorities must be addressed, including the development of biomarker-driven criteria (e.g., high CitH3 or MPO-DNA complexes) to identify “NET-high” RA patients, optimization of treatment timing and dosing sequences, and the creation of non-invasive NET imaging tools for real-time monitoring.